Medicines Co. (MDCO) Sells-Off with Alnylam (ALNY) Despite Providing Update
- Wall St. set to open lower, weighed down by GE
- British American Tobacco Offers to Acquire Remaining Shares of Reynolds American (RAI) for $56.50/Share
- General Electric (GE) Tops Q3 EPS by 2c; Updates FY16 EPS Outlook
- Pre-Open Stock Movers 10/21: (ALKS) (RAI) (PFPT) (MSFT) Higher; (SGY) (TWLO) (RRGB) Lower (more...)
- Oil rises on Russia's output freeze commitment
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Medicines Co. (NASDAQ: MDCO) is down 9.1% after-hours after Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced that upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) to suspend dosing, the Company has decided to discontinue development of revusiran, an investigational RNA interference (RNAi) therapeutic that was being developed for the treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM). This decision was made yesterday evening and has been communicated to investigators, study sites, and regulatory authorities.
Amid the news and sell-off, The Medicines Company (Nasdaq: MDCO) provided and update on its ORION-1 study and said no safety concerns were raised.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerecor (CERC) Surges with Alkermes (ALKS) Following Positive Depression Trial Results
- Stocks with Implied Volatility Movement
- Whole Foods Market (WFM) on Watch; Hep A Case Said Being Investigated in Detroit - Bloomberg
Create E-mail Alert Related CategoriesFDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!